LA JOLLA, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical firm traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), right this moment introduced that it has acquired an Issue Notification from the U.S. Patent and Trademark Office for a new patent which covers MN-166 (ibudilast) for the remedy of glioblastoma.
This new patent is predicted to run out no sooner than February 2039. The allowed claims cowl a technique of treating a affected person recognized with glioblastoma or recurrent glioblastoma, whereby the affected person expresses unmethylated MGMT, utilizing MN-166 (ibudilast) together with a number of different therapeutic brokers together with temozolomide (TMZ), carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, onartuzumab, patupilone (epothilone B), and recombinant oncolytic poliovirus (PVS-RIPO). The allowed claims cowl a big selection of doses of MN-166 (ibudilast) in addition to the opposite therapeutic brokers. The allowed claims additionally cowl several types of glioblastoma together with classical glioblastoma, proneural glioblastoma, mesenchymal glioblastoma, and neural glioblastoma.
Kazuko Matsuda, MD, PhD, MPH, Chief Medical Officer of MediciNova, Inc. commented, “We are very pleased to receive the issue notification for this new patent as it offers additional coverage compared to our other two patents covering glioblastoma. We have an ongoing clinical trial of MN-166 in combination with temozolomide for the treatment of recurrent glioblastoma at the Dana-Farber Cancer Institute, Harvard Medical School. Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone, and this data was presented at the American Society of Clinical Oncology (ASCO) annual meeting. Encouragingly, the FDA granted orphan-drug designation to MN-166 as adjunctive therapy to temozolomide for the treatment of glioblastoma based on this data.”
About Glioblastoma
According to the American Association of Neurological Surgeons, glioblastoma is an aggressive mind most cancers that usually leads to loss of life in the course of the first 15 months after prognosis. Glioblastoma develops from glial cells (astrocytes and oligodendrocytes), grows quickly, and generally spreads into close by mind tissue. Glioblastoma is assessed as Grade IV, the very best grade, within the World Health Organization (WHO) mind tumor grading system. The American Brain Tumor Association reviews that glioblastoma represents about 15% of all main mind tumors and roughly 10,000 circumstances of glioblastoma are recognized every year within the U.S. Despite many years of developments in neuroimaging, neurosurgery, chemotherapy and radiation remedy, solely modest enhancements have been achieved and the prognosis has not improved for people recognized with glioblastoma. Median survival is about 11-15 months for adults with extra aggressive glioblastoma (IDH-wildtype) who obtain customary remedy of surgical procedure, temozolomide, and radiation remedy.
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, together with macrophage migration inhibitory issue (MIF). It is in late-stage scientific growth for the remedy of neurodegenerative ailments resembling ALS (amyotrophic lateral sclerosis), progressive MS (a number of sclerosis), and DCM (degenerative cervical myelopathy); and can be in growth for glioblastoma, CIPN (chemotherapy-induced peripheral neuropathy), and substance use dysfunction. In addition, MN-166 (ibudilast) was evaluated in sufferers which might be in danger for creating acute respiratory misery syndrome (ARDS).
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical firm creating a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative ailments. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with a number of mechanisms of motion and powerful security profiles, MediciNova has 11 packages in scientific growth. MediciNova’s lead asset, MN-166 (ibudilast), is presently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive a number of sclerosis (MS). MN-166 (ibudilast) can be being evaluated in Phase 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver illness (NAFLD) is ongoing. MediciNova has a robust monitor document of securing investigator-sponsored scientific trials funded by way of authorities grants.
Statements on this press launch that aren’t historic in nature represent forward-looking statements inside the that means of the protected harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements embody, with out limitation, statements relating to the longer term growth and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements could also be preceded by, adopted by or in any other case embody the phrases “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “can,” “could,” “may,” “will,” “would,” “considering,” “planning” or related expressions. These forward-looking statements contain a variety of dangers and uncertainties that will trigger precise outcomes or occasions to vary materially from these expressed or implied by such forward-looking statements. Factors that will trigger precise outcomes or occasions to vary materially from these expressed or implied by these forward-looking statements embody, however usually are not restricted to, dangers of acquiring future associate or grant funding for growth of MN-166, MN-001, MN-221, and MN-029 and dangers of elevating adequate capital when wanted to fund MediciNova’s operations and contribution to scientific growth, dangers and uncertainties inherent in scientific trials, together with the potential value, anticipated timing and dangers related to scientific trials designed to satisfy FDA steerage and the viability of additional growth contemplating these components, product growth and commercialization dangers, the uncertainty of whether or not the outcomes of scientific trials shall be predictive of leads to later phases of product growth, the danger of delays or failure to acquire or keep regulatory approval, dangers related to the reliance on third events to sponsor and fund scientific trials, dangers relating to mental property rights in product candidates and the flexibility to defend and implement such mental property rights, the danger of failure of the third events upon whom MediciNova depends to conduct its scientific trials and manufacture its product candidates to carry out as anticipated, the danger of elevated value and delays on account of delays within the graduation, enrollment, completion or evaluation of scientific trials or vital points relating to the adequacy of scientific trial designs or the execution of scientific trials, and the timing of anticipated filings with the regulatory authorities, MediciNova’s collaborations with third events, the provision of funds to finish product growth plans and MediciNova’s capacity to acquire third get together funding for packages and lift adequate capital when wanted, and the opposite dangers and uncertainties described in MediciNova’s filings with the Securities and Exchange Commission, together with its annual report on Form 10-Ok for the yr ended December 31, 2021 and its subsequent periodic reviews on Form 10-Q and present reviews on Form 8-Ok. Undue reliance shouldn’t be positioned on these forward-looking statements, which communicate solely as of the date hereof. MediciNova disclaims any intent or obligation to revise or replace these forward-looking statements.
INVESTOR CONTACT:
Geoff O’Brien
Vice President
MediciNova, Inc.
[email protected]
